Vaccine Stocks Surge on Predicted COVID-19 Case Rise

Shares of COVID-19 vaccine makers like Moderna, Pfizer, BioNTech, and Novavax are rebounding as they pivot to new growth opportunities post-pandemic. Pfizer has acquired Seagen to focus on cancer drugs, Moderna awaits FDA approval for an RSV vaccine, BioNTech is diversifying its pipeline, and Novavax has a new licensing deal with Sanofi. These companies are outperforming the broader biotech sector despite past revenue declines.